On March 20, 2020, USTR announced that in "an effort to keep current on developments in our national fight against the coronavirus [COVID-19] pandemic," the agency "has opened a new docket for members of the public, business, and government agencies to submit comments" on possibly removing duties from additional medical care products of Chinese-origin. According to USTR, this comment process "supplements" the current Lists 3 and 4 exclusion processes and does not replace them.

Read more.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.